Patent foramen ovale (PFO) closure versus medical therapy for prevention of recurrent stroke in patients with prior cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials
- PMID: 29602258
- DOI: 10.1002/ccd.27615
Patent foramen ovale (PFO) closure versus medical therapy for prevention of recurrent stroke in patients with prior cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials
Abstract
Objectives: We performed a systematic review and meta-analysis of randomized controlled trials to assess the effect of closure of a patent foramen ovale (PFO) compared with medical therapy for the prevention of stroke in patients with prior cryptogenic stroke.
Background: The role of PFO closure in reducing risk of stroke in patients with prior cryptogenic stroke has been controversial.
Methods: We searched PubMed, Embase, CINAHL, and CENTRAL for randomized trials investigating PFO closure versus medical therapy. We assessed trial bias and the quality of evidence for main outcomes was rated using GRADE. The primary outcome of interest was the occurrence of stroke. Estimates of effect were pooled with a random-effects model. This study is registered with PROSPERO (CRD42017081579).
Results: We included five trials, comprising data for 3,440 adults randomized to receive PFO closure (n = 1,829) or medical therapy (n = 1,611). Mean follow-up ranged from 2 years to 5.4 years across the trials. Patients treated with PFO closure had a lower risk of stroke (RR 0.39, 95% CI 0.18-0.88, I2 = 57%, P = 0.02) compared with those treated with medical therapy. Subgroup analyses showed that the beneficial effect of PFO closure on a composite outcome of cerebrovascular events is more pronounced in patients with a large PFO shunt (RR 0.25, 95% CI 0.12-0.54, I2 = 0%, P = 0.0004), male patients (RR 0.34, 95% CI 0.15-0.75, I2 = 36%, P = 0.07), and those aged ≤45 years (RR 0.35, 95% CI 0.15-0.79, I2 = 0%, P = 0.01).
Conclusions: PFO closure reduced risk of stroke compared with medical therapy. PFO closure is a therapeutic option that should be offered to adults with cryptogenic stroke.
Keywords: meta-analysis; patent foramen ovale; patent foramen ovale closure; stroke; systematic review; transient ischemic attack.
© 2018 Wiley Periodicals, Inc.
Comment in
-
Patent foramen ovale closure for cryptogenic stroke: Effective, but only in select patients.Catheter Cardiovasc Interv. 2018 Jul;92(1):174-175. doi: 10.1002/ccd.27700. Catheter Cardiovasc Interv. 2018. PMID: 30917224
Similar articles
-
Long-term outcomes of patent foramen ovale closure or medical therapy after cryptogenic stroke: A meta-analysis of randomized trials.Catheter Cardiovasc Interv. 2018 Jul;92(1):176-186. doi: 10.1002/ccd.27636. Epub 2018 May 4. Catheter Cardiovasc Interv. 2018. PMID: 29726616
-
Transcatheter Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke: A Meta-Analysis of Randomized Controlled Trials.Cerebrovasc Dis. 2018;45(3-4):162-169. doi: 10.1159/000487959. Epub 2018 Mar 29. Cerebrovasc Dis. 2018. PMID: 29597192
-
Patent Foramen Ovale and Cryptogenic Stroke or Transient Ischemic Attack: To Close or Not to Close? A Systematic Review and Meta-Analysis.Cerebrovasc Dis. 2018;45(5-6):193-203. doi: 10.1159/000488401. Epub 2018 Apr 12. Cerebrovasc Dis. 2018. PMID: 29649819
-
Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.JACC Cardiovasc Interv. 2014 Aug;7(8):913-20. doi: 10.1016/j.jcin.2014.01.170. JACC Cardiovasc Interv. 2014. PMID: 25147037 Clinical Trial.
-
Percutaneous Closure of Patent Foramen Ovale in Patients with Cryptogenic Stroke - An Updated Comprehensive Meta-Analysis.Cardiovasc Revasc Med. 2019 Aug;20(8):687-694. doi: 10.1016/j.carrev.2018.09.010. Epub 2018 Sep 19. Cardiovasc Revasc Med. 2019. PMID: 30282597
Cited by
-
Advances in Percutaneous Patent Foramen Ovale Closure: From the Procedure to the Echocardiographic Guidance.J Clin Med. 2022 Jul 11;11(14):4001. doi: 10.3390/jcm11144001. J Clin Med. 2022. PMID: 35887765 Free PMC article. Review.
-
Patent foramen ovale in children: Unique pediatric challenges and lessons learned from adult literature.Ann Pediatr Cardiol. 2022 Jan-Feb;15(1):44-52. doi: 10.4103/apc.apc_67_21. Epub 2022 Jun 14. Ann Pediatr Cardiol. 2022. PMID: 35847406 Free PMC article. Review.
-
Updated Meta-analysis on the Closure of Patent Foramen Ovale in Reduction of Stroke Rates: the DEFENSE-PFO Trial Does not Change the Scenario.Braz J Cardiovasc Surg. 2018 Sep-Oct;33(5):511-521. doi: 10.21470/1678-9741-2018-0194. Braz J Cardiovasc Surg. 2018. PMID: 30517261 Free PMC article.
-
Long-term biocompatibility of fluorescent diamonds-(NV)-Z~800 nm in rats: survival, morbidity, histopathology, particle distribution and excretion studies (part IV).Int J Nanomedicine. 2019 Feb 14;14:1163-1175. doi: 10.2147/IJN.S189048. eCollection 2019. Int J Nanomedicine. 2019. PMID: 30863052 Free PMC article.
-
Atrial Fibrillation After Patent Foramen Ovale Closure: Incidence, Pathophysiology, and Management.J Am Heart Assoc. 2024 May 7;13(9):e034249. doi: 10.1161/JAHA.124.034249. Epub 2024 Apr 19. J Am Heart Assoc. 2024. PMID: 38639354 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical